When You Hear "You Don't Qualify" — What It Actually Means
You went through the PSMA PET scan. You waited for the results. Then you heard words no one wants to hear: "You don't meet the criteria." Maybe your scan wasn't positive enough. Maybe your kidney function was borderline. Or the hospital said they don't offer this treatment.
For many patients with metastatic castration-resistant prostate cancer (mCRPC), a denial for Lu-177 PSMA therapy—sometimes called Pluvicto or lutetium PSMA-617—can feel like a final answer. In many cases, it's not. Eligibility decisions depend on how doctors interpret your scan, what your organ function numbers are, and what treatments you've already had. These things can vary depending on who reviews them and where.
This article explains the eligibility criteria, why different centers give different answers, and what a real specialist second opinion looks like.
What Lu-177 PSMA Therapy Is and How It Works
Lu-177 PSMA therapy is a type of targeted cancer treatment called radioligand therapy. A radioactive molecule is attached to a compound that targets PSMA—prostate-specific membrane antigen—a protein found on most prostate cancer cells. When this compound attaches to a PSMA-expressing cell, it delivers radiation from the inside.
Normal tissue has far less PSMA than prostate cancer cells, so the therapy is more targeted than external radiation or chemotherapy. It moves through the bloodstream and reaches cancer deposits in bone and soft tissue, delivering radiation to cancer cells wherever they are in the body.
In 2022, the US Food and Drug Administration approved this therapy for men with PSMA-positive mCRPC. The Prostate Cancer Foundation has published information on the expanded approval, which now includes some patients who haven't yet received taxane chemotherapy.
The Formal Eligibility Criteria — In Plain Language
The eligibility criteria come from the patient groups in the clinical trials that tested the therapy. Here is what each criterion means in practice.
- A positive PSMA PET scan: This is the most important requirement. A scan using a tracer such as Ga-68 PSMA-11 or F-18 DCFPyL must confirm that cancer cells have enough PSMA expression. The scan must show at least one clearly PSMA-positive lesion. Most lesions should show PSMA positivity because lesions without it won't respond to the therapy.
- Castration-resistant disease: The cancer must still be growing even though testosterone has been suppressed to very low levels through hormone therapy or surgical castration.
- Prior treatment with an androgen receptor pathway inhibitor (ARPI): This typically means enzalutamide, abiraterone, apalutamide, or darolutamide. The original FDA approval also required at least one prior course of taxane chemotherapy. The expanded approval now covers some patients who haven't had chemotherapy yet.
- Adequate kidney function: Because your kidneys clear some of the Lu-177 PSMA, creatinine clearance must be above a defined threshold. Most centers use 30 to 40 mL/min as a minimum, but this varies.
- Acceptable blood counts: Hemoglobin, white cell count, and platelet levels must be high enough to tolerate the treatment.
- Adequate performance status: Most centers use the ECOG scale. A score of 0 or 1 is clearly acceptable. Some centers will consider ECOG 2 on a case-by-case basis.
If you were denied on one of these grounds, the critical question is: how was that determination made, by whom, and is there room for a different interpretation?
Why the Same Patient Gets Different Answers at Different Centers
Here is something that surprises many patients and families: when two experienced specialists review the same PSMA PET scan, they don't always reach the same eligibility conclusion.
Research published in the Journal of Nuclear Medicine examined how nuclear medicine physicians interpreted 68Ga-PSMA-11 PET/CT scans using criteria from the VISION trial. The study found that experienced physicians looking at the same images didn't always agree on whether a patient qualified. You can read the full study at PubMed Central.
This isn't a failure. PSMA PET scan interpretation requires clinical judgment. Lesion brightness, background signal, scan quality, and whether borderline lesions count as PSMA-positive all involve some interpretation. The line between enough and not enough PSMA expression isn't always clear.
If you were denied based on scan interpretation, a nuclear medicine physician with extensive Lu-177 PSMA experience may interpret your scan differently.
The Most Common Denial Reasons — and What They Mean for a Second Opinion
Your PSMA PET scan wasn't positive enough
This is the most common reason for denial. It may mean low overall PSMA expression, mixed results across lesions, or some lesions appearing PSMA-negative. Because interpretation varies between readers, an expert re-read of your actual scan images—not just the written report—is the most valuable step you can take. Our related article on what mixed PSMA PET scan results mean for eligibility explains more.
You haven't had chemotherapy yet
This was a requirement of the original VISION trial. The expanded approval and the PSMAfore trial—whose results are published at PubMed Central—now support access for some patients who haven't had chemotherapy but have progressed after ARPI therapy. If you were told you need chemotherapy before getting Lu-177 PSMA therapy, a second opinion on treatment order is worth seeking. Our article on whether to seek a second opinion about treatment sequencing before chemotherapy goes into more detail.
Your kidney function is borderline
Kidney function thresholds differ between centers. Some use 30 mL/min, others set it higher. Specialists in Lu-177 PSMA dosimetry can often give amino acid infusions or adjust your dose to reduce how much your kidneys are exposed to, making treatment possible for borderline patients.
Your performance status is too low
ECOG performance status cutoffs are guidelines that centers may interpret flexibly. If cancer burden—bone pain, fatigue, reduced mobility—rather than underlying frailty affects your performance status, some experienced centers will consider treatment on a case-by-case basis. Disease control may improve your function over time.
The center doesn't offer this treatment
This is an access issue, not a clinical one. If the referring center doesn't have a nuclear medicine department licensed to give Lu-177 therapy, they can't fully assess whether you qualify or provide the treatment. You can appropriately seek care at a high-volume center locally or internationally.
What a Specialist Second Opinion Actually Involves
A proper second opinion requires more than asking another oncologist. The right review involves a nuclear medicine physician who actively gives Lu-177 PSMA therapy, ideally with a medical oncologist who specializes in mCRPC and someone with dosimetry expertise.
A thorough second opinion should include:
- An independent review of your actual DICOM scan files, not just the written report
- Review of your full treatment history, including whether different treatment order might apply now
- Assessment of your current organ function, blood counts, and any other medical conditions
- Discussion of clinical trials you might qualify for, even if standard criteria aren't fully met
- A clear, honest explanation of what the current evidence means for your situation
For a complete explanation of the eligibility framework, our article on becoming a candidate for Lu-177 PSMA therapy explains every criterion in detail.
What to Submit for a Remote Eligibility Review
Many specialist centers—including those in India that serve international patients—can do a preliminary eligibility assessment remotely. To get a meaningful review, submit:
- Your PSMA PET/CT scan as DICOM image files, preferably not just the PDF report
- Ga-68 PSMA or F-18 PSMA scan report and images
- Biopsy or pathology report confirming prostate adenocarcinoma, Gleason score or Grade Group
- Full treatment history: all prior hormone therapies, chemotherapy, radiation, and any targeted agents
- Recent blood results: PSA, full blood count, creatinine, estimated glomerular filtration rate (eGFR), liver enzymes
- Any CT, MRI, or bone scan reports showing your current disease extent
- A summary of why you were previously declined, if the prior center provided one
The Clinical Evidence — Key Numbers in Plain Language
The main evidence comes from the phase III VISION trial. Researchers randomly assigned 831 men with PSMA-positive mCRPC who had already received hormone therapy and at least one course of chemotherapy to either standard care alone or standard care plus Lu-177 PSMA-617.
According to the National Cancer Institute's summary of the trial, men getting Lu-177 PSMA-617 had a median overall survival of 15.3 months, compared with 11.3 months in the standard care group. Imaging-based progression-free survival was 8.7 months with the treatment versus 3.4 months with standard care. These are significant differences in patients who had already progressed through multiple prior therapies.
The PSMAfore trial tested the therapy in patients who hadn't had chemotherapy yet. It showed that Lu-177 PSMA-617 may be appropriate earlier in treatment for men who have progressed after ARPI therapy but not yet had chemotherapy. We're still learning which patients benefit most from this therapy.
Expected Benefits and Limitations — Honestly Stated
Lu-177 PSMA therapy may help control disease, reduce PSA levels, relieve bone pain, and extend the time before further progression. It is not a cure. Eligible patients respond differently. Patients who do respond typically see benefits for several months, often with real improvements in quality of life.
Doctors usually check your response after two cycles by monitoring PSA trends and, when needed, repeat imaging. Some patients see rapid PSA reductions in the first cycle. Others see slower responses, or in some cases limited benefit despite meeting eligibility criteria.
Side Effects and Safety
Lu-177 PSMA therapy typically causes milder side effects than chemotherapy. The most commonly reported effects in clinical trials include fatigue, dry mouth (because PSMA appears in salivary glands), mild nausea, and temporary reductions in blood counts. Doctors give amino acid infusions during each cycle to protect your kidneys—this is standard at experienced centers. Serious side effects are rare. Most patients receive the therapy as an outpatient procedure and go home the same day.
What International Patients Should Expect
For patients in the United Kingdom, Australia, Canada, the United States, Germany, France, the UAE, New Zealand, and across Africa, access to Lu-177 PSMA therapy depends on local availability and funding. In some countries the treatment is approved but public health systems limit access through long waiting times or strict criteria. Others require private funding or travel to a specialist center.
India is a major center for Lu-177 PSMA therapy. Cancer centers there offer the treatment at much lower cost than most Western countries, with experienced nuclear medicine teams and shorter waiting periods for international patients. Our guide on planning your Lu-177 PSMA treatment in India explains what international patients need to prepare—both medically and logistically—before traveling.
A remote eligibility assessment based on your records can give you a clear preliminary answer about whether you qualify before you commit to any travel or further appointments.
When to Talk to Your Doctor
If you have been denied Lu-177 PSMA therapy, consider asking your current team or seeking a specialist referral to answer these questions: Which exact eligibility criterion wasn't met? Did a nuclear medicine physician with direct Lu-177 experience review your PSMA PET scan? Did your team consider the expanded approval for patients who haven't had chemotherapy? Are there active clinical trials you might qualify for? Could a dosimetry review or repeat organ function assessment change the picture?
Getting a second opinion complements your current team. It's standard in cancer care. Many patients initially denied got treatment after an expert reviewed their records.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
What is the most common reason patients are denied Lu-177 PSMA therapy?
The most common reason is a PSMA PET scan considered not sufficiently positive — meaning the scan did not show enough PSMA expression across cancer lesions, or that some lesions appeared PSMA-negative alongside positive ones. Because scan interpretation involves clinical judgement, the same scan reviewed by a different specialist may reach a different conclusion. Other common reasons include prior treatment history not yet meeting criteria, borderline kidney function, or a performance status scored too low for the treating centre's threshold.
Can a different nuclear medicine specialist reach a different eligibility conclusion from the same PSMA PET scan?
Yes — research published in the Journal of Nuclear Medicine found only moderate-to-substantial agreement between experienced readers interpreting PSMA PET scans using VISION trial criteria. This means interpretation can vary between specialists reviewing the same images. An independent re-read of your actual DICOM scan files by a nuclear medicine physician with extensive Lu-177 eligibility experience may produce a different conclusion from the original interpretation, particularly in borderline cases.
Do I need to have had chemotherapy before I can access Lu-177 PSMA therapy?
The original FDA approval required prior taxane chemotherapy. However, the expanded approval — supported by the PSMAfore trial — now covers some patients who have progressed after androgen receptor pathway inhibitor therapy but have not yet received chemotherapy. If you were denied specifically because you had not yet had chemotherapy, this is worth discussing with a specialist familiar with the current expanded criteria and with the PSMAfore trial data.
What records should I submit for a specialist eligibility review?
The most important records are your PSMA PET/CT scan images — ideally full DICOM files rather than just the PDF report — alongside your scan report, histopathology report, complete treatment history, recent blood results including PSA and kidney function markers, and any CT or MRI imaging showing current disease extent. A written summary of why you were previously declined is also helpful. The more complete your submission, the more accurately a specialist can assess your candidacy without needing to repeat tests.
If my kidney function is borderline, does that automatically exclude me from Lu-177 PSMA therapy?
Not necessarily. Kidney function thresholds vary between centres, and some experienced centres offer amino acid infusion protocols or dose adjustments that reduce renal exposure during treatment. If your kidney function is borderline rather than severely impaired, a specialist with dosimetry experience may be able to develop a treatment plan that makes therapy feasible. This is a conversation best had directly with a nuclear medicine physician who regularly administers Lu-177 PSMA therapy.
How do I find a specialist who can give me a second opinion on Lu-177 PSMA eligibility?
Look for a nuclear medicine physician at a centre that actively administers Lu-177 PSMA therapy — not just one that reads PSMA PET scans for diagnosis. High-volume academic cancer centres and dedicated nuclear medicine units are the best places to start. Internationally, specialist centres in India accept remote submissions of scan images and medical records for preliminary eligibility assessments, which can be a practical starting point for patients in countries with limited local access to radioligand therapy expertise.